The purpose of this trial is to compare the morbidity and mortality of CRS-HIPEC using
mitomycin-C versus melphalan for colorectal peritoneal carcinomatosis. Morbidity and
mortality will measured using the Comprehensive Complication Index (CCI) score, Common
terminology criteria for adverse events (CTCAE version 4.03), and the Clavien-Dindo
Classification.

The goal of this study is to find the best ways to increase colorectal cancer (CRC)
screening.

This is a clinical research study of an investigational (FDA IND-BB 10091) treatment for
patients with advanced colorectal cancer that no longer responds to standard therapies.

The treatment is being evaluated for its effect on tumor growth. It consists of small beads
that contain mouse cancer cells from a mouse kidney cancer cell line. The cells in the beads
produce substances that have been shown to slow or stop the growth of tumors in experimental
animals, veterinary patients, and 37 humans with colorectal cancers in a Phase 1 and 2
safety trials.